The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Treatment considerations for elderly and frail patients with lung cancer
Markus Joerger, MD, PhD, Kantonsspital St. Gallen, St. Gallen, Switzerland, discusses key considerations in managing elderly and frail patients with lung cancer. He emphasizes the importance of accurately assessing performance status and incorporating tools such as comorbidity indices and frailty scores to inform treatment decisions. Integrating these differentiated assessments into multidisciplinary tumour board (MTB) discussions may help optimize treatment planning, particularly for patients with advanced-stage disease or reduced functional capacity. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
